latanoprost

Details

Files
Generic Name:
latanoprost
Project Status:
Complete
Therapeutic Area:
glaucoma and ocular hypertension
Manufacturer:
Laboratoires Théa
Call for patient/clinician input open:
Brand Name:
Monoprost
Project Line:
Reimbursement Review
Project Number:
SR0541-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
glaucoma and ocular hypertension
Date NOC Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:

Key Milestones2

Call for patient input posted September 26, 2017
Patient group input closed November 15, 2017
Clarification:

- No patient input submission received

Submission received October 25, 2017
Submission accepted for review November 08, 2017
Review initiated November 09, 2017
Draft CDR review report(s) sent to applicant February 01, 2018
Comments from applicant on draft CDR review report(s) received February 12, 2018
Redaction requests from applicant on draft CDR review report(s) received February 20, 2018
CDR review team's comments on draft CDR review report(s) sent to applicant March 09, 2018
Canadian Drug Expert Committee (CDEC) meeting March 21, 2018
CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plans April 03, 2018
Embargo period ended and validation of redacted CDR review report(s) received April 17, 2018
CDEC Final Recommendation issued to applicant and drug plans April 24, 2018
CDEC Final Recommendation posted April 27, 2018
Final CDR review report(s) and patient input posted May 17, 2018